Accordingly, and taking into account the comparative oncologic aspects, the combined application of BTK and PI3K inhibitors in the treatment of canine DLBCL bears significance for dogs as patients and as an in vivo model for humans with DLBCL. Here, PIK3CD is linked to diffuse large B-cell lymphoma.